JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Apellis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

28.6 1.89

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.02

Максимум

28.89

Ключови измерители

By Trading Economics

Приходи

50M

-42M

Продажби

12M

178M

Марж на печалбата

-23.615

Служители

705

EBITDA

50M

-30M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+28.14% upside

Дивиденти

By Dow Jones

Следващи печалби

30.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.2B

3.6B

Предишно отваряне

26.71

Предишно затваряне

28.6

Настроения в новините

By Acuity

34%

66%

108 / 371 Класиране в Healthcare

Apellis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.10.2025 г., 20:49 ч. UTC

Печалби

Correction to Thermo Fisher Article on Oct. 22

23.10.2025 г., 23:51 ч. UTC

Пазарно говорене

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23.10.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

23.10.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23.10.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23.10.2025 г., 22:58 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

23.10.2025 г., 22:57 ч. UTC

Пазарно говорене

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23.10.2025 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

How Trump Sparked a New Era of State Capitalism -2-

23.10.2025 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23.10.2025 г., 22:17 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23.10.2025 г., 21:41 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23.10.2025 г., 21:05 ч. UTC

Печалби

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.10.2025 г., 20:35 ч. UTC

Печалби

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23.10.2025 г., 20:28 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23.10.2025 г., 20:15 ч. UTC

Пазарно говорене
Печалби

Global Commodities Roundup: Market Talk

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q Adj EPS $1.71

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q Sales $5.52B

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q EPS $1.67

23.10.2025 г., 20:09 ч. UTC

Печалби

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23.10.2025 г., 20:07 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

23.10.2025 г., 20:07 ч. UTC

Пазарно говорене
Печалби

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23.10.2025 г., 20:07 ч. UTC

Печалби

Blackstone Looks to IPOs for Investment Exits -- Update

23.10.2025 г., 20:05 ч. UTC

Печалби

Intel 3Q Gross Margin 38.2% >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel: 4Q Guidance Excludes Altera >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel Sees 4Q Adj EPS 8c >INTC

Сравнение с други в отрасъла

Ценова промяна

Apellis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

28.14% нагоре

12-месечна прогноза

Среден 36.06 USD  28.14%

Висок 60 USD

Нисък 18 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Apellis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

17 ratings

10

Купи

6

Задържане

1

Продай

Настроение

By Acuity

108 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat